EVAHEART: an implantable centrifugal blood pump for long-term circulatory support.
EVAHEART: an implantable centrifugal blood pump for long-term circulatory support.
复制标题
DOI：
10.1007/bf02919636
复制
发表时间：
2002-11-01
期刊：
影响因子：
--
通讯作者：
Kurosawa, Hiromi
中科院分区：
文献类型：
--
作者：
Yamazaki, Kenji;Kihara, Shinichiro;Kurosawa, Hiromi
目的：我们开发了“EVAHEART”：一种紧凑型离心血泵系统，作为植入式左心室辅助装置，用于长期循环支持。55 x 64 mm泵由纯钛制成，重370 g。整个血液接触表面覆盖有类金刚石碳（DLC）或2-甲基丙烯酰氧乙基磷酰胆碱（MPC）的抗血栓涂层，以改善血液相容性。在2600 rpm下，测量了在100 mmHg压力下超过12 L/min的流量。轴的密封采用带循环冷却系统的低温机械密封。EVAHEART表现出可接受的低溶血率，标准化溶血指数为0.005 +/- 0.002 g/100 L。方法：我们在7头小牛的长期体内实验中评价了泵。结果：所有病例的泵流量维持在5-9 L/min，泵功耗稳定在9-10 W，血浆游离血红蛋白水平均小于15 mg/dl，密封系统在整个实验过程中表现出良好的密封性能。在术后第200、222、142、90、151、155和133天按计划处死小牛。结论：EVAHEART离心血泵在长期的体内实验中表现出良好的性能。
OBJECTIVE: We developed "EVAHEART": a compact centrifugal blood pump system as an implantable left ventricular assist device for long-term circulatory support. The 55 x 64 mm pump is made from pure titanium, and weighs 370 g. The entire blood-contacting surface is covered with an anti-thrombogenic coating of diamond like carbon (DLC) or 2-methacryloyloxyethyl phosphorylcholine (MPC) to improve blood compatibility. Flows exceeding 12 L/min against 100 mmHg pressure at 2600 rpm was measured. A low-temperature mechanical seal with recirculating cooling system is used to seal the shaft. EVAHEART demonstrated an acceptably low hemolysis rate with normalized index of hemolysis of 0.005 +/- 0.002 g/100L.METHODS: We evaluated the pump in long-term in-vivo experiments with seven calves. Via left thoracotomy, we conducted left ventricular apex-descending aorta bypass, placing the pump in the left thoracic cavity.RESULTS: Pump flow rates was maintained at 5-9 L/min, pump power consumption remained stable at 9-10 W in all cases, plasma free Hb levels were less than 15 mg/dl, and the seal system showed good seal capability throughout the experiments. The calves were sacrificed on schedule on postoperative day 200, 222, 142, 90, 151, 155, and 133. No thrombi formed on the blood contacting surface with either the DLC or MPC coating, and no major organ thromboembolisms occurred except for a few small renal infarcts.CONCLUSION: EVAHEART centrifugal blood pump demonstrated excellent performance in long-term in-vivo experiments.